DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies
Current vaccines against SARS-CoV-2, based on the original Wuhan sequence,
induce antibodies with different degrees of cross-recognition of new viral variants
of concern. Despite potent responses generated in vaccinated and infected
individuals, the Omicron (B.1.1.529) variant causes breakthrough infections,
facilitating viral transmission. We previously reported a vaccine based on a cyclic
peptide containing the 446-488 S1 sequence (446-488cc) of the SARS-CoV-2
spike (S) protein from Wuhan isolate. To provide the best immunity against
Omicron, here we compared Omicron-specific immunity induced by a Wuhanbased
446-488cc peptide, by a Wuhan-based recombinant receptor-binding
domain (RBD) vaccine and by a new 446-488cc peptide vaccine based on the
Omicron sequence. Antibodies induced by Wuhan peptide 446-488cc in three
murine strains not only recognized the Wuhan and Omicron 446-488 peptides
similarly, but also Wuhan and Omicron RBD protein variants. By contrast,
antibodies induced by the Wuhan recombinant RBD vaccine showed a much
poorer cross-reactivity for the Omicron RBD despite similar recognition of Wuhan
and Omicron peptide variants. Finally, although the Omicron-based 446-488cc
peptide vaccine was poorly immunogenic in mice due to the loss of T cell epitopes,
co-immunization with Omicron peptide 446-488cc and exogenous T cell
epitopes induced strong cross-reactive antibodies that neutralized Omicron
SARS-CoV-2 virus. Since mutations occurring within this sequence do not alter
T cell epitopes in humans, these results indicate the robust immunogenicity of
446-488cc-based peptide vaccines that induce antibodies with a high crossrecognition
capacity against Omicron, and suggest that this sequence could be
included in future vaccines targeting the Omicron variant., This work was supported by Instituto de Salud Carlos III, Fondo
Europeo de Desarrollo Regional “Una manera de hacer Europa”
under grant PI20/00260, Gobierno de Navarra under grant 0011-
3597-2020-000024 to PS and by Paula & Rodger Riney Foundation to
JJL. This research was also supported by Spanish Research Council
(CSIC) grants 202120E079 (to JG-A) and 2020E84 (to ME), Spanish
Ministry of Science and Innovation (MCIN)/Spanish Research
Agency (AEI)/10.13039/501100011033 grant (PID2020-114481RBI00;
to JG-A and ME), and Centro de Investigación Biomédica en
Red de Enfermedades Infecciosas (CIBERINFEC) co-financed with
FEDER funds (to JG-A). This research work was also funded by the
European Commission-NextGenerationEU, through CSIC’s Global
Health Platform (PTI Salud Global) (to JG-A and ME). JG-A and ME
also acknowledge financial support from the Spanish State Research
Agency, AEI/10.13039/501100011033, through the “Severo Ochoa”
Programme for Centres of Excellence in R&D (SEV-2013-0347, SEV-
2017-0712)., Peer reviewed
Project:
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI20-00260
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-114481RB-I00
,
MINECO SEV-2013-0347
,
AEI SEV-2017-0712
View at: http://hdl.handle.net/10261/309597